The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy

Naim Abu-Freha, Zohar Levi, Anat Nevo-Shor, Revital Guterman, Ruhama Elhayany, Avraham Yitzhak, Dana Zelnik Yovel, Daniel L. Cohen, Haim Shirin

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Aim: We aimed to investigate the association between Glucagon-like-peptide-1 receptors agonists (GLP1-RA) use and gastric residue on esophagogastroduodenoscopy (EGD). Methods: A multicenter, retrospective study included all EGDs conducted across seven gastroenterology departments. EGDs with the diagnosis of “poor preparation” or described as a poor preparation in the endoscopist's report were considered as gastric residue. Results: 120,879 EGDs were included in the analysis. Of these, 1671 patients treated with GLP1-RA were compared to 119,208 without GLP1-RA treatment. Of the GLP1-RA group, 93 (5.6 %) had gastric residue compared to 2327 (2.0 %) among the non-GLP1-RA group (p < 0.001). Sup-group analysis: 71 (6.2 %) of the 1141 DM patients treated with GLP1-RA compared to 307 (3.0 %) of the 10,152 DM patients without GLP1-RA treatment (p < 0.001). Additionally, 22 (4.2 %) of 503 non-DM patients treated with GLP1-RA had gastric residue compared to 2065 (2.0 %) of the non-DM non-GLP1-RA group (n = 109,056) (p < 0.001). In multivariate analysis, DM and GLP1-RA were both found to be independent risk factors for excess gastric residue. Conclusion: Our results may have important clinical relevance for EGD preparation among GLP1-RA treated patients, either requiring a longer fasting time prior to EGD or holding the medication prior to EGD according to the half-life of the drug.

    Original languageEnglish
    Article number111900
    JournalDiabetes Research and Clinical Practice
    Volume217
    DOIs
    StatePublished - 1 Nov 2024

    Keywords

    • Diabetes mellitus
    • EGD
    • GLP1
    • Gastric residue
    • Upper endoscopy

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Fingerprint

    Dive into the research topics of 'The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy'. Together they form a unique fingerprint.

    Cite this